• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Atopic Dermatitis Onset in a Melanoma Patient Under Pembrolizumab Therapy: A Case of Successful Treatment with Dupilumab.

作者信息

Tolino Ersilia, Proietti Ilaria, Skroza Nevena, Guardo Antonio Di, Fraia Marco Di, Dybala Agnieszka, Potenza Concetta

机构信息

From the Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Fiorini Hospital, 04019 Terracina, Italy E-mail:

出版信息

Indian J Dermatol. 2024 May-Jun;69(3):268-269. doi: 10.4103/ijd.ijd_123_23. Epub 2024 Jun 26.

DOI:10.4103/ijd.ijd_123_23
PMID:39119322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11305492/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2e5/11305492/fee3a63d9d60/IJD-69-268-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2e5/11305492/fee3a63d9d60/IJD-69-268-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2e5/11305492/fee3a63d9d60/IJD-69-268-g001.jpg

相似文献

1
Atopic Dermatitis Onset in a Melanoma Patient Under Pembrolizumab Therapy: A Case of Successful Treatment with Dupilumab.帕博利珠单抗治疗的黑色素瘤患者发生特应性皮炎：度普利尤单抗成功治疗一例
Indian J Dermatol. 2024 May-Jun;69(3):268-269. doi: 10.4103/ijd.ijd_123_23. Epub 2024 Jun 26.
2
Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.成人特应性皮炎患者接受度普利尤单抗治疗的评估：一项单中心真实世界经验。
J Cosmet Dermatol. 2022 Oct;21(10):4781-4787. doi: 10.1111/jocd.14785. Epub 2022 Jan 30.
3
[Principles of modern diagnosis and treatment of atopic dermatitis and bronchial asthma: Clinical case].[特应性皮炎与支气管哮喘的现代诊断与治疗原则：临床病例]
Ter Arkh. 2022 Mar 15;94(3):427-433. doi: 10.26442/00403660.2022.03.201430.
4
Development of Café-Au-Lait-Macule Lesions in a Patient After Dupilumab Therapy for Atopic Dermatitis.一名特应性皮炎患者接受度普利尤单抗治疗后出现咖啡斑样皮损
Cureus. 2023 Jul 27;15(7):e42581. doi: 10.7759/cureus.42581. eCollection 2023 Jul.
5
Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.特应性皮炎患者度普利尤单抗相关眼表疾病的管理。
Swiss Med Wkly. 2021 Aug 20;151:w30020. doi: 10.4414/SMW.2021.w30020.
6
Safety of dupilumab in patients with atopic dermatitis: expert opinion.治疗特应性皮炎患者的度普利尤单抗的安全性：专家意见。
Expert Opin Drug Saf. 2021 Sep;20(9):997-1004. doi: 10.1080/14740338.2021.1939673. Epub 2021 Jun 19.
7
Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.儿童中重度特应性皮炎患者接受度普利尤单抗治疗后出现银屑病样皮炎。
Pediatr Dermatol. 2021 Nov;38(6):1500-1505. doi: 10.1111/pde.14820. Epub 2021 Oct 14.
8
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.度普利尤单抗治疗特应性皮炎患者的长期疗效：RELIEVE-AD研究3年随访结果
Dermatol Ther (Heidelb). 2023 Sep;13(9):2107-2120. doi: 10.1007/s13555-023-00965-5. Epub 2023 Aug 8.
9
Dupilumab-associated cicatrizing ocular disease.度普利尤单抗相关的瘢痕性眼病。
Am J Ophthalmol Case Rep. 2022 Apr 9;26:101528. doi: 10.1016/j.ajoc.2022.101528. eCollection 2022 Jun.
10
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.度普利尤单抗为中度至重度特应性皮炎成人患者提供快速且持续的具有临床意义的缓解。
Acta Derm Venereol. 2021 Nov 10;101(11):adv00585. doi: 10.2340/actadv.v101.307.

引用本文的文献

1
Dupilumab for the Treatment of Cutaneous Immune-Related Adverse Events: A Systematic Review.度普利尤单抗治疗皮肤免疫相关不良事件的系统评价
Int J Dermatol. 2025 Oct;64(10):1825-1832. doi: 10.1111/ijd.17850. Epub 2025 May 15.
2
Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment.免疫检查点抑制剂治疗后2型辅助性T细胞炎症性疾病的综述
Biomedicines. 2024 Aug 19;12(8):1886. doi: 10.3390/biomedicines12081886.

本文引用的文献

1
Atopic dermatitis, dupilumab and cancers: a case series.特应性皮炎、度普利尤单抗与癌症：病例系列
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e651-e652. doi: 10.1111/jdv.17264. Epub 2021 Jun 11.
2
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.度普利尤单抗在接受 3 期开放标签扩展研究的中重度特应性皮炎患者中显示出长期安全性和疗效。
J Am Acad Dermatol. 2020 Feb;82(2):377-388. doi: 10.1016/j.jaad.2019.07.074. Epub 2019 Jul 30.
3
Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review.
与调节白细胞介素-13 和白细胞介素-4 信号相关的潜在风险：系统评价。
Drug Saf. 2018 May;41(5):489-509. doi: 10.1007/s40264-017-0636-9.
4
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.抗程序性细胞死亡（PD）-1 治疗转移性黑色素瘤患者的皮肤不良事件（AE）：单机构队列。
J Am Acad Dermatol. 2016 Mar;74(3):455-61.e1. doi: 10.1016/j.jaad.2015.10.029. Epub 2016 Jan 12.
5
Immunosuppressive drugs and cancer.免疫抑制药物与癌症
Toxicology. 2003 Apr 1;185(3):229-40. doi: 10.1016/s0300-483x(02)00612-1.